A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors

NCT02136069 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

397

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Etrolizumab
DRUG: Infliximab
OTHER: Placebo (IV)
OTHER: Placebo (Injection)

Sponsor

Hoffmann-La Roche